Cargando…
Candesartan, rather than losartan, improves motor dysfunction in thioacetamide-induced chronic liver failure in rats
Minimal hepatic encephalopathy is more common than the acute syndrome. Losartan, the first angiotensin-II receptor blocker (ARB), and candesartan, another widely-used ARB, have protected against developing fibrogenesis, but there is no clear data about their curative antifibrotic effects. The curren...
Autores principales: | Murad, H.A., Gazzaz, Z.J., Ali, S.S., Ibraheem, M.S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Associação Brasileira de Divulgação Científica
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609604/ https://www.ncbi.nlm.nih.gov/pubmed/28953991 http://dx.doi.org/10.1590/1414-431X20176665 |
Ejemplares similares
-
Health-care costs of losartan and candesartan in the primary treatment of hypertension
por: Henriksson, M, et al.
Publicado: (2011) -
Cost-effectiveness of candesartan versus losartan in the primary preventive treatment of hypertension
por: Granström, Ola, et al.
Publicado: (2012) -
Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension
por: Kjeldsen, S E, et al.
Publicado: (2010) -
Candesartan in heart failure
por: Ripley, Toni L, et al.
Publicado: (2006) -
Candesartan cilexetil in the treatment of chronic heart failure
por: Baguet, Jean-Philippe, et al.
Publicado: (2009)